⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Phoenix Molecular Designs and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Phoenix Molecular Designs
↗Vancouver, Canada
Phoenix Molecular Designs (PhoenixMD) is a clinical-stage biopharmaceutical company headquartered in Vancouver, BC, with clinical operations in San Diego, CA. The company focuses on developing precision cancer therapeutics and companion diagnostics by targeting kinases, specifically ribosomal S6 kinase (RSK), which is implicated in various cancers, heart disease, and inflammation.
The company's lead candidate, PMD-026, is a first-in-class RSK inhibitor designed to treat Triple-Negative Breast Cancer (TNBC) and other refractory cancers. PhoenixMD utilizes a proprietary platform that integrates computational biology, medicinal chemistry, and functional cancer biology to advance its pipeline.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2012
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$14.7M
Investors:Susan G. Komen Foundation
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:National Cancer Institute (NCI), MD Anderson Cancer Center, Roche (Companion Diagnostics), Kyushu University, University of Tuebingen
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Sandra E. Dunn - Founder & CEO
Scientific Founders:Sandra E. Dunn
Board Members:Sandra E. Dunn, Leena Das-Young
LINKS
Website:phoenixmd.ca
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Phoenix Molecular Designs. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.